As leader is freed from prison, Samsung Biologics nabs massive investment from parent company's $205B spending spree
One of biotech manufacturing’s giants has announced a massive investment in its operations over the next three years.
Samsung Biologics will receive a share of a $205 billion investment from its parent company, along with Samsung Electronics, as the Korean company ramps up its semiconductor, biopharmaceuticals and telecommunications units. More than $154 billion of that money will be spent right in South Korea, as the company plans to create 40,000 new jobs by 2023. And M&A is very much on the table.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.